Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...
The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.
GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 7 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.